Skip to main content

Table 4 Promoter hypermethylation of biomarkers in colorectal adenomas (test and validation sets) compared with the patients clinico-pathological features and tumor phenotype

From: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas

  CNRIP1 FBN1 INA MAL SNCA Panel
  M U M U M U M U M U Pos Neg
Tumors             
   No 101/111 10/111 77/111 34/111 39/111 72/111 93/111 18/111 59/111 52/111 103/111 8/111
Tumor phenotype             
   MSI 2 0 2 0 1 1 2 0 1 1 2 0
   MSS 52 6 39 19 24 34 49 9 32 26 52 6
   P value NS NS NS NS NS NS
Sex             
   Male 50 4 41 13 22 32 46 8 31 23 51 3
   Female 51 6 36 21 17 40 47 10 28 29 52 5
   P value NS NS NS NS NS NS
Tumor site - 2 groups             
   Proximal 15 2 11 6 5 12 14 3 9 8 15 2
   Distal 85 7 64 28 33 59 77 15 50 42 86 6
   P value NS NS NS NS NS NS
Tumor site - 3 groups             
   Right 15 2 11 6 5 12 14 3 9 8 15 2
   Left 54 6 37 23 17 43 49 11 31 29 55 5
   Rectum 31 1 27 5 16 16 28 4 19 13 31 1
   P value NS 7.5E-2 NS NS NS NS
Dysplasia             
   High 7 0 5 2 2 5 7 0 5 2 7 0
   Low 94 10 72 32 37 67 86 18 54 50 96 8
   P value NS NS NS NS NS NS
Tumor size             
   < 10 mm 45 2 31 16 12 35 39 8 23 24 44 3
   ≥ 10 mm 55 7 44 18 26 36 52 10 36 26 57 5
   P value NS NS NS NS NS NS  
  1. Pearson's chi-square and Fisher's exact tests were used to calculate P-values. Associations between SPG20 promoter hypermethylation and tumor phenotype have been published elsewhere [9].
  2. Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; Neg, biomarker panel negative; NS, not significant; Pos, biomarker panel positive. A positive biomarker panel is defined as methylation of two or more of the following biomarkers: CNRIP1, FBN1, INA, MAL, SNCA and SPG20.